← All compounds · evidence tier first, by design
| Use | E1 | E2 | E3 | E4 | E5 | E6 | E7 | E8 |
|---|---|---|---|---|---|---|---|---|
| E3 Raising GH and IGF-1 levels (pharmacodynamic marker, healthy adults) | E3 | |||||||
| E6 Growth in GHRH deficiency | E6 | |||||||
| E8 Muscle gain, fat loss, recovery, sleep and anti-ageing (gray-market claims) | E8 | |||||||
| E8 Visceral fat in people with HIV | E8 |
CJC-1295
A modified GHRH(1-29) amide analogue with a C-terminal reactive group designed to bind covalently to circulating albumin (the developer's 'drug affinity complex'), which extended its half-life to several days in humans. A 29-residue amidated GHRH analogue without the albumin-binding group has been identified in material sold under the CJC-1295 name.
Non-standard residues or modifications: no plain one-letter sequence
Also: CJC-1295 with DAC, CJC 1295 · Codes: CJC-1295
A synthetic, long-acting analogue of growth hormone-releasing hormone (GHRH) developed by ConjuChem in the 2000s. Its only registered efficacy trial, in people with HIV and abdominal fat, was terminated in 2006 and never reported. It has no approval anywhere checked and no active sponsor. It is sold as a "research chemical" with claims of muscle gain, fat loss, better sleep and "anti-ageing". FDA has identified serious adverse events associated with it.
- US C gray market
- EU C gray market
- UK ? not verified
- CA C gray market
- AU ? not verified
- JP ? not verified
- CN ? not verified
01Regulatory status, by jurisdiction
| Jurisdiction | Status | Detail and primary source |
|---|---|---|
| US | Not approved | Not approved: no application found in Drugs@FDA (openFDA query, retrieval date). CJC-1295 was placed in Category 2 (significant safety risks) of FDA's 503A interim policy; it now appears on FDA's list of substances 'nominated but withdrawn', i.e. removed from Category 2 because the nominator withdrew the nomination, not because FDA resolved the safety concerns, which the page still states.“FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.”Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026) · retrieved 2026-10-10 |
| US | Not approved | CJC-1295 does not appear in Category 1, 2 or 3 of FDA's list of bulk drug substances nominated for 503A compounding (updated 14 May 2026). It is not on the 503A bulks list and is not a component of any FDA-approved drug product.“Category 1: Bulk Drug Substances Under Evaluation”Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Updated May 14, 2026) · retrieved 2026-10-10 |
| EU | Not approved | No product containing CJC-1295 appears in EMA's downloadable medicines dataset (2,748 records, generated 10 Oct 2026), which covers centrally authorised medicines, refusals and withdrawn applications. National authorisations were not checked individually.“This includes information on marketing authorisations of centrally authorised medicines and post-authorisation procedures.”Download medicine data | European Medicines Agency (EMA) · retrieved 2026-10-10 |
| CA | Not approved | Queries of Health Canada's Drug Product Database for the active ingredient and brand name CJC-1295 returned no products under any status on the retrieval date.“Search by drug identification number”Drug Product Database online query · retrieved 2026-10-10 |
| UK AU JP CN | Not yet verified from a primary source. No status is shown rather than an unsourced one. | |
Sport (WADA): Prohibited · class S2.2.4. “growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)” WADA source
02What the human evidence shows
Raising GH and IGF-1 levels (pharmacodynamic marker, healthy adults)
No randomised controlled trial in humans has been published for this use.
Two randomised, placebo-controlled, ascending-dose studies in healthy adults (lasting 28 and 49 days) found dose-dependent rises in plasma GH and IGF-1 lasting days after a single dose, with an estimated half-life of about 6 to 8 days; no serious adverse reactions were reported. A separate uncontrolled before-and-after study in healthy young men found raised trough and mean GH with preserved pulsatility, and higher IGF-1, one week after a single dose. These are small, short studies of a hormone marker, not of any clinical outcome.
- [1] Dose-dependent increases in plasma GH and IGF-1 lasting days in healthy adults in two randomised, placebo-controlled dose-escalation studies; estimated half-life 5.8 to 8.1 days
- [2] Raised trough and mean GH and IGF-1 with preserved GH pulsatility one week after a single dose in healthy young men (uncontrolled)
Registered-study counts: ClinicalTrials.gov intervention search “CJC-1295”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Growth in GHRH deficiency
No human trial of any design has been published for this use.
In mice genetically lacking GHRH, five weeks of treatment from one week of age normalised body weight, length and body composition when given every 24 hours, with lesser effects at longer intervals. This is a deficiency model; it does not show effects in animals or people with normal GHRH. No human growth study exists.
- [3] Normalised body weight, length and body composition in GHRH-knockout mice
Registered-study counts: ClinicalTrials.gov intervention search “CJC-1295”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Muscle gain, fat loss, recovery, sleep and anti-ageing (gray-market claims)
No human trial of any design has been published for this use.
No published study in humans or animals has tested any of these outcomes. Published human studies measured only hormone levels (GH and IGF-1) in healthy adults over weeks (see the pharmacodynamic entry above). Raised hormone levels are a laboratory measure, not evidence of muscle gain, fat loss, better sleep or any health benefit.
- [4] Product-identity finding, not efficacy: a seized preparation contained a 29-residue amidated peptide consistent with the sequence marketed as CJC-1295
Registered-study counts: ClinicalTrials.gov intervention search “CJC-1295”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Visceral fat in people with HIV
No human trial of any design has been published for this use.
A randomised placebo-controlled Phase 2 trial in 120 people with HIV-associated visceral obesity (NCT00267527, ConjuChem) began in December 2005 and is registered as terminated in 2006. No reason is given on the registry and no results were posted or published, so it is not counted as a published trial. No published study in humans or animals has tested CJC-1295 on visceral fat.
Registered-study counts: ClinicalTrials.gov intervention search “CJC-1295”, fetched 2026-10-10. Registered studies include trials of other uses; the gap between registered and reported is itself a finding.
Key registered trials
| NCT | Title (as registered) | Phase | Status |
|---|---|---|---|
| NCT00267527 | A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity | 2 | Terminated |
03Safety signals
There are no adequate human safety data. The absence of reported harm is not evidence of safety.
- Increased heart rate and systemic vasodilatory reaction [5]
FDA's compounding safety-risk summary states it has identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and that available clinical data are limited. The underlying case details are not published there. - Immunogenicity and impurity concerns [5]
FDA states compounded CJC-1295 may pose a risk of immunogenicity for certain routes and raises peptide-impurity and characterisation concerns.
04What is unknown
- No human efficacy data for any clinical outcome; the published human studies (two small randomised placebo-controlled studies and one uncontrolled study, all in healthy adults) measured only GH and IGF-1 and lasted under two months
- No human safety data beyond short dose-finding studies in small numbers of healthy adults; no data on repeated exposure over months or years
- Why the only efficacy trial (NCT00267527) was terminated is not stated on the registry, and its data were never reported
- Effects of sustained elevation of GH and IGF-1 from a long-acting analogue on glucose metabolism, cancer risk or the heart are unstudied
- Products sold as CJC-1295 may contain a different peptide: a 29-residue analogue without the albumin-binding group was identified in a seized preparation, so the half-life and effects of what is in a given vial are unknown
- Regulatory status in the UK, Australia, Japan and China was not verified from regulator sources for this record
05Product quality
No independent purity results have been published for this compound yet. The purity programme will publish full methods and vendor-named results, passes and failures, once its protocol has had legal review.
06Citations
- Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults (2006). doi:10.1210/jc.2005-1536
- Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog (2006). doi:10.1210/jc.2006-1702
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse (2006). doi:10.1152/ajpendo.00201.2006
- Identification of CJC‐1295, a growth‐hormone‐releasing peptide, in an unknown pharmaceutical preparation (2010). doi:10.1002/dta.233
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Every DOI is resolved against Crossref and every NCT number against ClinicalTrials.gov, title for title, before publication. Regulatory sources are cited inline above with a verbatim quote and retrieval date.
07Mechanism
CJC-1295 is a GHRH analogue designed to bind albumin after absorption, prolonging its action; in rats it activated pituitary GHRH receptors, and in healthy adults it raised GH and IGF-1 for several days.
Mechanism is placed last on purpose: a plausible mechanism is not evidence that a compound works in people.
Reviewed by OSMF research team (AI-assisted, source-verified) on 2026-10-10. Found an error? It goes in the corrections log: report it.